StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report released on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of LPCN stock opened at $5.20 on Tuesday. Lipocine has a 1 year low of $2.31 and a 1 year high of $5.95. The firm has a fifty day moving average price of $4.04 and a 200-day moving average price of $3.27. The company has a market cap of $27.66 million, a price-to-earnings ratio of -1.70 and a beta of 1.02.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.11. The business had revenue of $0.22 million for the quarter. Equities research analysts expect that Lipocine will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in Lipocine in the 1st quarter worth $54,000. State Street Corp lifted its stake in Lipocine by 7.5% in the 1st quarter. State Street Corp now owns 327,405 shares of the specialty pharmaceutical company’s stock worth $449,000 after purchasing an additional 22,788 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Lipocine by 524.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 74,428 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Lipocine by 474.5% during the 2nd quarter. Renaissance Technologies LLC now owns 81,006 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 66,906 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Lipocine during the 2nd quarter valued at about $160,000. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.